Get the app
US › Healthcare

Alx Oncology Holdings  (ALXO)

US · Healthcare · Biotechnology

$1.06+6.00%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-18.0M
EPS
$-0.13
EPS estimate
$-0.15

EPS came in at -0.13 against a street estimate of -0.15 — a beat of 13.3%.

Key statistics

Market cap
$135.5M
Forward P/E
0.0
P/B
1.47
Book value
$0.98
EPS (TTM)
$-1.13
52-week high
$2.66
52-week low
$0.89
50-day MA
$1.76
200-day MA
$1.83
Beta
0.48

Analyst view

Analysts rate Alx Oncology Holdings  a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $4.60.

Shareholding

Insiders
0.89%
Institutions
84.70%

Largest institutional holders

FundStake
RA Capital Management, LLC9.41%
venBio Partners LLC9.32%
BlackRock Inc5.35%
Redmile Group, LLC5.35%
Blackstone Inc4.77%
Driehaus Capital Management LLC4.36%
SILVERARC CAPITAL MANAGEMENT, LLC4.15%
TCG Crossover Management, LLC4.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alx Oncology Holdings  — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.